Low‐dose febuxostat exhibits a superior renal‐protective effect and non‐inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double‐centre, randomized, controlled study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13794
Abstract: The present study compared the efficacy and safety of low‐dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA). read more here.
Keywords: dose febuxostat; allopurinol chronic; chronic kidney; kidney disease ... See more keywords